332 related articles for article (PubMed ID: 18179307)
1. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
Brousseau G; Rourke BP; Burke B
Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
[TBL] [Abstract][Full Text] [Related]
2. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
Grossberg GT
Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
4. Is antidepressant treatment associated with reduced cognitive decline in Alzheimer's disease?
Mossello E; Boncinelli M; Caleri V; Cavallini MC; Palermo E; Di Bari M; Tilli S; Sarcone E; Simoni D; Biagini CA; Masotti G; Marchionni N
Dement Geriatr Cogn Disord; 2008; 25(4):372-9. PubMed ID: 18354253
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of Alzheimer's disease].
Bombois S; Lebert F; Vellas B; Pasquier F
Rev Prat; 2005 Nov; 55(17):1913-9. PubMed ID: 16396232
[TBL] [Abstract][Full Text] [Related]
6. Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.
Cummings JL; Masterman DL
J Clin Psychiatry; 1998; 59 Suppl 13():23-30. PubMed ID: 9771827
[TBL] [Abstract][Full Text] [Related]
7. Neurochemical basis for symptomatic treatment of Alzheimer's disease.
Francis PT; Ramírez MJ; Lai MK
Neuropharmacology; 2010; 59(4-5):221-9. PubMed ID: 20156462
[TBL] [Abstract][Full Text] [Related]
8. [Cholinergic deficiency syndrome as an indicator for the cholinesterase inhibitors].
Lemstra AW; Eikelenboom P; van Gool WA
Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2201-3. PubMed ID: 14640055
[TBL] [Abstract][Full Text] [Related]
9. [Treatment for non-cognitive symptoms in Alzheimer's disease].
Vilalta-Franch J; López-Pousa S; Llinàs-Reglà J
Rev Neurol; 1999 Nov 1-15; 29(9):819-24. PubMed ID: 10696656
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors: A new class of psychotropic compounds.
Cummings JL
Am J Psychiatry; 2000 Jan; 157(1):4-15. PubMed ID: 10618007
[TBL] [Abstract][Full Text] [Related]
11. [The pharmacotherapy of the cognitive disorders in Alzheimer's disease. Guidelines for rational drug use--a review].
Strnad J; Bahro M
Dtsch Med Wochenschr; 2000 Jul; 125(27):835-9. PubMed ID: 10929539
[No Abstract] [Full Text] [Related]
12. Alzheimer's drugs deliver fringe benefits. Cholinesterase inhibitors improve more than just memory.
Auerbach SH
Health News; 2003 Mar; 9(3):1-2. PubMed ID: 12703432
[No Abstract] [Full Text] [Related]
13. The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach.
Davidson M; Stern RG
Psychiatr Clin North Am; 1991 Jun; 14(2):461-82. PubMed ID: 2062728
[TBL] [Abstract][Full Text] [Related]
14. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
Sugimoto H
Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's disease: cognitive and behavioral pharmacotherapy.
Cummings JL; Mendez MF
Conn Med; 1997 Sep; 61(9):543-52. PubMed ID: 9334509
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of Alzheimer's disease].
López OL; Becker JT
Rev Neurol; 2002 Nov 1-15; 35(9):850-9. PubMed ID: 12436384
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of Alzheimer's disease.
Grossberg GT
J Clin Psychiatry; 2003; 64 Suppl 9():3-6. PubMed ID: 12934967
[TBL] [Abstract][Full Text] [Related]
18. Clinical inquiries. Do patients at high risk of Alzheimer's disease benefit from early treatment?
Holt J; Stiltner L; Wallace R; Raetz J
J Fam Pract; 2009 Jun; 58(6):320-2. PubMed ID: 19508846
[TBL] [Abstract][Full Text] [Related]
19. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
Relkin NR
Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
[TBL] [Abstract][Full Text] [Related]
20. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.
Wynn ZJ; Cummings JL
Dement Geriatr Cogn Disord; 2004; 17(1-2):100-8. PubMed ID: 14564129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
